Non-invasive control of gene editing in vivo by photoswitchable Cas12f and focused ultrasound.

Nucleofection-Based CRISPR/Cas Delivery in Human T Cells for Immunotherapy Applications.

Electroporation-based delivery of CRISPR/Cas systems has emerged as a powerful and versatile approach for gene editing in primary human T cells, enabling efficient, transient, and nonviral modification while minimizing genomic integration risks. This chapter focuses on the principles and practical implementation of ele...

Chemically modified CRISPR enzymes for multi-organ genome editing in vivo

Delivery remains the main obstacle to the development of in vivo genome editing therapies. CRISPR ribonucleoproteins confer high editing activity with transient exposure but lack intrinsic cell entry and targeting. Here we introduce PERCEPT, a delivery platform featuring reversible, covalent modification of CRISPR enzy...

Programming primary human T cells to deliver gene editing machinery

Clinical applications of gene editors including CRISPR-Cas9 are limited by the cell-type specificity and tissue penetrance of current in vivo delivery options. Cell-mediated gene editor delivery could overcome these obstacles. To date, systems utilizing immortalized cell lines have demonstrated gene editor delivery in...

Recent advances in delivery strategies for CRISPR-based genome editing

The rapid development of CRISPR genome editing technologies has established a transformative paradigm within biomedical research, drug discovery, and gene therapy. Despite the robust nuclease activity and programmable targeting exhibited by these systems, the clinical translation of CRISPR-mediated therapeutics remai...

Ultrasound-Mediated CRISPR Delivery and Sonogenetic Modulation for Precision Therapeutics.

Ultrasound-CRISPR technologies are elaborates potential as a powerful tool that enables targeted, and image-guided genetic interventions, capable of advancing the outcomes of gene therapy as a widespread clinical practice.

Structure-guided discovery and engineering of miniature CRISPR-Cas12m for epigenome editing.